1. Fibrillin-1 and fibrillin-1-derived asprosin in adipose tissue function and metabolic disorders
- Author
-
Muthu L. Muthu and Dieter P. Reinhardt
- Subjects
musculoskeletal diseases ,0301 basic medicine ,medicine.medical_specialty ,Adipose tissue ,Review ,White adipose tissue ,Biochemistry ,Neonatal Progeroid Syndrome ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Molecular Biology ,biology ,business.industry ,Cell Biology ,medicine.disease ,030104 developmental biology ,Endocrinology ,Adipogenesis ,030220 oncology & carcinogenesis ,biology.protein ,Lipodystrophy ,Metabolic syndrome ,business ,Fibrillin ,Elastin - Abstract
The extracellular matrix microenvironment of adipose tissue is of critical importance for the differentiation, remodeling and function of adipocytes. Fibrillin-1 is one of the main components of microfibrils and a key player in this process. Furin processing of profibrillin-1 results in mature fibrillin-1 and releases the C-terminal propeptide as a circulating hunger hormone, asprosin. Mutations in the fibrillin-1 gene lead to adipose tissue dysfunction and causes Marfan syndrome, marfanoid progeroid lipodystrophy syndrome, and neonatal progeroid syndrome. Increased TGF-β signaling, altered mechanical properties and impaired adipogenesis are potential causes of adipose tissue dysfunction, mediated through deficient microfibrils. Circulating asprosin on the other hand is secreted primarily by white adipose tissue under fasting conditions and in obesity. It increases hepatic glucose production and drives insulin secretion and appetite stimulation through inter-organ cross talk. This review discusses the metabolic consequences of fibrillin-1 and fibrillin-1-derived asprosin in pathological conditions. Understanding the dynamic role of fibrillin-1 in the adipose tissue milieu and of circulating asprosin in the body can provide novel mechanistic insights into how fibrillin-1 may contribute to metabolic syndrome. This could lead to new management regimens of patients with metabolic disease.
- Published
- 2020
- Full Text
- View/download PDF